Administration of corticosteroid therapy for HELLP syndrome in pregnant women: evidences from seven randomized controlled trials

• Published in: Hypertension in pregnancy 2023-12, Vol.42 (1), p.2276726-2276726
• Main Authors: Sun, Wei-Jing, Hu, Jing, Zhang, Qing, Shan, Jin-Mei
• Format: Article
• Language: English
• Subjects: comorbidities; corticosteroids; eclampsia; HELLP; pregnant women
• ISSN: 1064-1955; 1525-6065
• DOI: 10.1080/10641955.2023.2276726

BACKGROUNDHELLP syndrome, featuring hemolysis, elevated liver enzymes, and thrombocytopenia, is life-threatening disease of pregnancy that triggers comorbidities in both pregnant women and the fetus/newborn. This study provides an updated systematic review and meta-analysis of relevant studies to assess the therapeutic efficacy of corticosteroids in maternal and neonatal outcomes.METHODSRandomized control trials (RCTs) regarding the use of corticosteroids in the HELLP population from three electronic databases, including Ovid MEDLINE, Ovid EMBASE, andCochrane Central Register of Controlled Trials, were searched from database inception to 23 March 202323 March 2023.RESULTSA total of 485 patients treated with corticosteroids from 7 RCTs were included. Compared to placebo, corticosteroids therapy failed to significantly improve the maternal outcomes regard to maternal morbidity (RR = 1.36, 95%CI [0.45, 4.10]), eclampsia (RR = 1.16, 95%CI [0.76, 1.77]), acute renal failure (RR = 0.71, 95%CI [0.41, 1.22]), pulmonary edema (RR = 0.34, 95%CI [0.10, 1.15]) and oliguria (RR = 1.08, 95%CI [0.75, 1.54]). In addition, pooled data showed that it wasn't significant differences between corticosteroids therapy and placebo regarding neonatal outcomes.CONCLUSIONSThis study compared the efficacy of corticosteroids in patients with HELLP syndrome, revealing that corticosteroids did not provide any significant benefit in clinical outcomes for pregnant women and newborns with HELLP. The conclusions of this study must be verified by a larger sample of high-quality RCTs.